Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 9239530, 7 pages
http://dx.doi.org/10.1155/2016/9239530
Research Article

Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1

1Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411 Tartu, Estonia
2Centre for Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411 Tartu, Estonia
3Laboratory Animal Centre, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411 Tartu, Estonia
4Tartu University Hospital, 8 L. Puusepa Street, 51014 Tartu, Estonia

Received 12 January 2016; Accepted 22 February 2016

Academic Editor: Fabrizio Barbetti

Copyright © 2016 Tuuli Sedman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. G. Barrett, “Mitochondrial diabetes, DIDMOAD and other inherited diabetes syndromes,” Best Practice and Research: Clinical Endocrinology & Metabolism, vol. 15, no. 3, pp. 325–343, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. T. M. Strom, K. Hörtnagel, S. Hofmann et al., “Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein,” Human Molecular Genetics, vol. 7, no. 13, pp. 2021–2028, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. Marshall, M. A. Permutt, A. R. Paciorkowski et al., “Phenotypic characteristics of early Wolfram syndrome,” Orphanet Journal of Rare Diseases, vol. 8, article 64, 2013. View at Publisher · View at Google Scholar
  4. K. Matsunaga, K. Tanabe, H. Inoue et al., “Wolfram syndrome in the japanese population; molecular analysis of wfs1 gene and characterization of clinical features,” PLoS ONE, vol. 9, no. 9, Article ID e106906, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Rohayem, C. Ehlers, B. Wiedemann et al., “Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype,” Diabetes Care, vol. 34, no. 7, pp. 1503–1510, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Cheurfa, G. M. Brenner, A. F. Reis et al., “Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the data from epidemiological study on the insulin resistance syndrome (DESIR) prospective study,” Diabetologia, vol. 54, no. 3, pp. 554–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. L. Minton, A. T. Hattersley, K. Owen et al., “Association studies of genetic variation in the WFS1 gene and type 2 diabetes in U.K. populations,” Diabetes, vol. 51, no. 4, pp. 1287–1290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Hattersley, J. Bruining, J. Shield, P. Njolstad, and K. C. Donaghue, “The diagnosis and management of monogenic diabetes in children and adolescents,” Pediatric Diabetes, vol. 10, supplement 12, pp. 33–42, 2009. View at Publisher · View at Google Scholar
  9. J. Shirakawa, R. Tanami, Y. Togashi et al., “Effects of liraglutide on β-cell-specific glucokinase-deficient neonatal mice,” Endocrinology, vol. 153, no. 7, pp. 3066–3075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Ishihara, S. Takeda, A. Tamura et al., “Disruption of the WFS1 gene in mice causes progressive β-cell loss and impaired stimulus-secretion coupling in insulin secretion,” Human Molecular Genetics, vol. 13, no. 11, pp. 1159–1170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. C. Riggs, E. Bernal-Mizrachi, M. Ohsugi et al., “Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis,” Diabetologia, vol. 48, no. 11, pp. 2313–2321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Noormets, S. Kõks, M. Muldmaa, L. Mauring, E. Vasar, and V. Tillmann, “Sex differences in the development of diabetes in mice with deleted wolframin (Wfs1) gene,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 5, pp. 271–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Krass, K. Rünkorg, E. Vasar, and V. Volke, “Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice,” Acta Neuropsychiatrica, vol. 24, no. 5, pp. 296–300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Krass, A. Volke, K. Rünkorg et al., “GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment,” Acta Neuropsychiatrica, vol. 27, no. 1, pp. 25–32, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Kõks, U. Soomets, J. L. Paya-Cano et al., “Wfs1 gene deletion causes growth retardation in mice and interferes with the growth hormone pathway,” Physiological Genomics, vol. 37, no. 3, pp. 249–259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. S. Surwit, M. N. Feinglos, E. G. Livingston, C. M. Kuhn, and J. A. McCubbin, “Behavioral manipulation of the diabetic phenotype in ob/ob mice,” Diabetes, vol. 33, no. 7, pp. 616–618, 1984. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Luuk, M. Plaas, S. Raud et al., “Wfs1-deficient mice display impaired behavioural adaptation in stressful environment,” Behavioural Brain Research, vol. 198, no. 2, pp. 334–345, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Akiyama, M. Hatanaka, Y. Ohta et al., “Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice,” Diabetologia, vol. 52, no. 4, pp. 653–663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Wu, S. Wei, N. Petersen et al., “Synaptotagmin-7 phosphorylation mediates GLP-1–dependent potentiation of insulin secretion from β-cells,” Proceedings of the National Academy of Sciences, vol. 112, no. 32, pp. 9996–10001, 2015. View at Publisher · View at Google Scholar
  20. S. Lu, K. Kanekura, T. Hara et al., “A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 49, pp. E5292–E5301, 2014. View at Publisher · View at Google Scholar
  21. R. Ahluwalia, K. Perkins, D. Ewins, and N. Goenka, “Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?” Diabetic Medicine, vol. 26, no. 8, pp. 834–835, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Mondragon, D. Davidsson, S. Kyriakoudi et al., “Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia,” PLoS ONE, vol. 9, no. 8, Article ID e104873, 2014. View at Publisher · View at Google Scholar · View at Scopus